Valirx wins Canadian patent for 'gene-silencing' technology
ValiRx, the AIM listed life sciences firm, saw its share price surge on news that its 'gene-silencing' technology has received patent approval in Canada.
ValiRx, the AIM listed life sciences firm, saw its share price surge on news that its 'gene-silencing' technology has received patent approval in Canada.
It already has patents for the US, Europe and Australia.
ValiRx is developing treatments which "silence" so called rebellious genes that can cause cancer and various neurological problems.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The firm also announced today that it has extended its agreement with Imperial College London for cancer therapeutic work.
Production of ValiRx's main "VAL101" compound is "going to plan and has been optimised and simplified." The company argues this will reduce costs and add future value.
Dr. Satu Vainikka, ValiRx's Chief Executive, said of the patent grant: "The filing of this latest patent extends our global geographic patent coverage and I believe it represents a value marker for the company, as we further progress the GeneICE pre-clinical programme."
At 9:13am shares in the company were at 0.502p, a rise of 14.2% on the day. This year ValiRx has seen its value rise 99%.
BS
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
What happens if you can’t pay your tax bill, and what is "Time to Pay"?
Millions are due to file their tax return this Friday as the self-assessment deadline closes. Though the nightmare is not over until you pay the taxman what you owe - or face a penalty. But what happens if you can't afford to pay HMRC your tax bill, and what is "Time to Pay"?
By Kalpana Fitzpatrick Published
-
What does Rachel Reeves’s plan for growth mean for UK investors?
Rachel Reeves says she is going “further and faster” to kickstart the UK economy, but investors are unlikely to be persuaded
By Katie Williams Published